ATC Group: C02DB02 Hydralazine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of C02DB02 in the ATC hierarchy

Level Code Title
1 C Cardiovascular system
2 C02 Antihypertensives
3 C02D Arteriolar smooth muscle, agents acting on
4 C02DB Hydrazinophthalazine derivatives
5 C02DB02 Hydralazine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 0.1 g

Active ingredients in C02DB02

Active Ingredient Description
Hydralazine

Hydralazine is a direct acting vasodilator which exerts its effects principally on the arterioles. Its precise mode of action is not known.

Related product monographs

Title Information Source Document Type  
APRESOLINE Solution for injection Health Products and Food Branch (CA) MPI, CA: SPM

Medicines in this ATC group

Australia (AU)

Brazil (BR)

Canada (CA)

Hong Kong (HK)

Ireland (IE)

Japan (JP)

Malta (MT)

Mexico (MX)

New Zealand (NZ)

Nigeria (NG)

Singapore (SG)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.